Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders

References

• American Diabetes Association. American Diabetes Association standards of medical care in diabetes–2015. Diabetes Care. 2015;38:S1–S94.
   Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–e292.
   PubMed Web of Science ®Google Scholar
• Narayan KMV, Zhang P, Kanaya AM. Diabetes: the pandemic and potential solutions. In Jamison DT, Breman JG, Measham AR, et al. eds. Disease Control Priorities in Developing Countries. 2nd ed. Washington, DC: World Bank; 2006.
   Google Scholar
• Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diab. 2008;26:77–82.
   Google Scholar
• Manuel DG, Schultz SE. Health-related quality of life and health-adjusted life expectancy of people with diabetes in Ontario, Canada, 1996-1997. Diabetes Care. 2004;27:407–414.
   PubMed Web of Science ®Google Scholar
• Narayan KM, Boyle JP, Thompson TJ, et al. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290:1884–1890.
   PubMed Web of Science ®Google Scholar
• Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003;22:331–339.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey data. Morbidity and Mortality Weekly Report. Available from: www.cdc.gov/mmwr/preview/mmwrhtml/mm6331a5.htm. MMWR. 2014;63:678.
   Google Scholar
• Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015;21:1–87.
   PubMed Web of Science ®Google Scholar
• Kushner RF, Ryan DH. Assessment and lifestyle management of patients with obesity: clinical recommendations from systematic reviews. JAMA. 2014;312:943–952.
   PubMed Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129:S102–S138.
   PubMed Web of Science ®Google Scholar
• Kushner RF. Weight loss strategies for treatment of obesity. Prog Cardiovasc Dis. 2014;56:465–472.
   PubMed Web of Science ®Google Scholar
• Swift DL, Johannsen NM, Lavie CJ, et al. The role of exercise and physical activity in weight loss and maintenance. Prog Cardiovasc Dis. 2014;56:441–447.
   PubMed Web of Science ®Google Scholar
• Thomas DM, Martin CK, Redman LM. Lorcaserin improves dietary adherence: New insights from an energy balance analysis. Presented at Obesity Week, November 2-7, 2015; Los Angeles, California.
   Google Scholar
• BELVIQ (lorcaserin hydrochloride) US prescribing information. Woodcliff Lake, NJ: Eisai Inc; 2014.
   Google Scholar
• Martin CK, Redman LM, Zhang J, et al. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab. 2011;96:837–845.
   PubMed Web of Science ®Google Scholar
• Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine(2C) agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325:577–587.
   PubMed Web of Science ®Google Scholar
• Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–256.
   PubMed Web of Science ®Google Scholar
• Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–3077.
   PubMed Web of Science ®Google Scholar
• O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20:1426–1436.
   PubMed Web of Science ®Google Scholar
• Weissman NJ, Sanchez M, Koch GG, et al. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging. 2013;6:560–567.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX, Soliman W, Shanahan W, et al. Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and non-responders. Presented at Obesity Week, November 11-16, 2013; Atlanta, Georgia.
   Google Scholar
• Heisler LK, Cowley MA, Kishi T, et al. Central serotonin and melanocortin pathways regulating energy homeostasis. Ann N Y Acad Sci. 2003;994:169–174.
   PubMed Web of Science ®Google Scholar
• Fan W, Dinulescu DM, Butler AA, et al. The central melanocortin system can directly regulate serum insulin levels. Endocrinology. 2000;141:3072–3079.
   PubMed Web of Science ®Google Scholar
• Zhou L, Sutton GM, Rochford JJ, et al. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab. 2007;6:398–405.
   PubMed Web of Science ®Google Scholar
• Xu Y, Berglund ED, Sohn JW, et al. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate insulin sensitivity in liver. Nat Neurosci. 2010;13:1457–1459.
   PubMed Web of Science ®Google Scholar
• Wade JM, Juneja P, MacKay AW, et al. Synergistic impairment of glucose homeostasis in ob/ob mice lacking functional serotonin 2C receptors. Endocrinology. 2008;149:955–961.
   PubMed Web of Science ®Google Scholar
• Berglund ED, Liu C, Sohn JW, et al. Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeo-stasis. J Clin Invest. 2013;123:5061–5070.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract. 2013;19:1–48.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Garber AJ, Mechanick JI, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014;20:977–989.
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342–362.
   PubMed Web of Science ®Google Scholar
• Xu Y, Jones JE, Kohno D, et al. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron. 2008;60:582–589.
   PubMed Web of Science ®Google Scholar
• Smith SR, O’Neil PM, Astrup A, et al. Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight-loss outcomes. Obesity (Silver Spring). 2014;22:2137–2146.
   PubMed Web of Science ®Google Scholar